Rayzon (parecoxib)
- Region
- 🇪🇺 EU
- Active substance
- parecoxib
- Company
- Pharmacia Europe EEIG
- Status
- Withdrawn
- Therapeutic area
- Pain, Postoperative
- EU approval
- Fri 22 Mar 2002
- Application
- EMEA/H/C/000382
- ATC
- M01AH04
- Official record
- www.ema.europa.eu
Indication
For the short-term treatment of postoperative pain.The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient's overall risks (see sections 4.3, 4.4).
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Dynastat Authorised · Pfizer Europe MA EEIG
- 🇪🇺 Xapit Withdrawn · Pharmacia Europe EEIG
Follow Rayzon
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.